anacardic acid has been researched along with Corneal Neovascularization in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; He, L; Liu, M; Pang, X; Wu, Y; Yi, Z; Zhang, J; Zhang, L | 1 |
1 other study(ies) available for anacardic acid and Corneal Neovascularization
| Article | Year |
|---|---|
Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Topics: Anacardic Acids; Angiogenesis Inhibitors; Animals; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Corneal Neovascularization; Dose-Response Relationship, Drug; Focal Adhesion Kinase 1; GTP Phosphohydrolases; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Neovascularization, Pathologic; Prostatic Neoplasms; Protein-Tyrosine Kinases; rho GTP-Binding Proteins; rho-Associated Kinases; Signal Transduction; src-Family Kinases; Time Factors; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2011 |